Your Meds Can Turn Into POISON

Omeprazole is one of the most overprescribed medications in the speaker's experience. Many older patients have been on it for years without re-evaluation. In the first clinical case, an early-80s man had been taking 40 mg of omeprazole despite no reflux symptoms for years and a normal upper endoscopy two years prior. The speaker therefore decided it was unnecessary and formulated a slow step-down plan. He emphasized that this is a common scenario—patients often remain on acid suppressants indefinitely simply because no one has reviewed the original indication. Beyond the case, he noted that the risk of long-term PPI use (such as nutrient malabsorption, kidney injury, and increased infection risk) adds to the imperative to deprescribe when no longer needed.

The speaker presented a meta-analysis of 13 trials with over 160,000 participants that crystallized this risk-benefit trade-off. While the relative reduction in heart attacks and strokes is modest, the absolute increase in major hemorrhage becomes particularly concerning in the elderly, who are more prone to falls and already have a higher background bleeding rate. Clinical guidelines now explicitly recommend against routine aspirin for primary prevention in adults over 70, and this has become a standard part of the speaker's deprescribing assessments. He noted that in his practice, many patients were prescribed aspirin decades ago under older paradigms and have continued it unquestioningly. In both patient 1 and patient 3, he and the patients decided together to stop aspirin after reviewing these data.

In the second clinical case, a late-60s woman using a walker and at high fall risk was on zopiclone and amitriptyline for sleep. The speaker immediately identified these as dangerous and planned to remove them. He cited the dangers of a frail person getting up at night while sedated. To mitigate the loss of sleep aid, he proposed sustained-release melatonin, referencing a meta-analysis of 14 studies showing a significant reduction in sleep onset latency and a review supporting improved sleep quality. He also leveraged his clinic's free health improvement practitioner to coach the patient on sleep hygiene, creating a comprehensive non-drug strategy. This approach reflects his standard practice for deprescribing sleep medications in the elderly.

The speaker's second patient had a sodium of 130 mmol/L while on three medications known to cause hyponatremia: bendroflumethiazide, sertraline, and candesartan. He identified bendroflumethiazide as the most potent driver and decided to stop it. He was emboldened by the recent trial showing that reducing blood pressure medications in the frail elderly did not increase overall mortality. He set a new upper limit of 140 mmHg for this patient, and outlined a backup plan: if BP exceeded that, he would add a low-dose calcium channel blocker (which does not lower sodium) and, if necessary, a low-dose beta blocker. This stepwise, sodium-sparing strategy reshapes how he manages hypertension in hyponatremic patients.

The speaker's second patient was on sertraline 100 mg along with bendroflumethiazide and candesartan, all of which can lower sodium. He planned to stop the thiazide first, but also halved the sertraline dose to further mitigate hyponatremia. He stressed that mental health cannot be neglected, so the plan included ensuring the patient is connected to her community—a form of social prescribing that can support mood without relying solely on medication. This illustrates his balanced approach: address the drug-related harm without leaving the underlying condition untreated.

The speaker mentioned amitriptyline as part of patient 2's regimen. After addressing the more immediately dangerous zopiclone, the plan was to reduce and ideally stop amitriptyline. Although not as sedating as zopiclone, amitriptyline still contributes to fall risk and was being used off-label for sleep, making it appropriate to deprescribe. The weaning would occur after the patient had adapted to melatonin and sleep hygiene, ensuring a gentle transition.

The speaker's third patient, a mid-70s man with diabetes and heart failure, had an HbA1c of 6.7%, which he deemed too aggressive. Citing geriatric guidelines, he recommended a target of 8% to avoid hypoglycemic falls. He halved the Lantus dose and stopped gliclazide entirely. He then introduced empagliflozin 10 mg, an SGLT2 inhibitor that carries a strong indication for both diabetes and heart failure, providing glucose-lowering without hypoglycemia and a proven survival benefit in heart failure. The beta blocker, already part of the regimen, reinforced the need to reduce insulin because of drug interactions that mask hypoglycemia. This case encapsulates his philosophy: stop harmful medications, but judiciously add evidence-based ones when the indication is robust.

The speaker elaborated each phase in detail. Information gathering includes not only the medication list and side effects but also the patient's overall health status and personal goals—what matters most to them (e.g., staying at home, avoiding falls). Identification of candidate medications involves educating the patient on each drug's current evidence-based benefits and harms, acknowledging that these change with age. The patient then weighs these facts against their own priorities. If they choose to stop a medication, the third phase is to design a concrete tapering plan (dose reductions, timeline) and schedule follow-up to monitor for both expected and unexpected reactions. The speaker stressed that many patients are at particular risk: those with multiple health problems, transitions in care where different prescribers add drugs, limited life expectancy where preventive medications have no time to help, or difficulties with adherence. He also noted that certain drug classes are specifically flagged by the American Geriatrics Society as potentially inappropriate. This framework transforms deprescribing from an afterthought into a routine, systematic process.

The speaker introduced this principle when discussing the backup plan for his second patient after stopping bendroflumethiazide. He explained that rather than using a high dose of any single medication, he would first try a low-dose calcium channel blocker, which has little impact on sodium, and if that was insufficient, add a low-dose beta blocker. This approach minimizes side-effect risk and avoids reintroducing a drug that lowers sodium. It represents a strategic shift from monotherapy maximization to rational low-dose polypharmacy, especially relevant in the frail where intolerance and adverse effects are magnified.

The speaker described the study as an examination of the impact of reducing the number of antihypertensive drugs in frail elderly patients. Contrary to expectations, the researchers found no rise in overall mortality when medications were reduced, even though blood pressure would likely increase. This evidence directly informed the speaker's decision to stop the thiazide diuretic bendroflumethiazide in a frail patient with hyponatremia and accept a systolic blood pressure up to 140 mmHg before considering new agents. The speaker now feels comfortable deprescribing BP medications more aggressively, using a strategy of low-dose multi-drug combinations (calcium channel blocker, beta blocker) that spare sodium levels rather than keeping patients on problematic drugs. This shift represents a significant change in day-to-day clinical practice, moving from a default of maintaining all BP meds to a patient-centered reassessment of benefit versus harm.

In patient 2, a frail late-60s woman using a walker, the speaker identified zopiclone and amitriptyline as major fall risks. He planned to slowly wean off zopiclone completely, then later taper amitriptyline. To address the inevitable sleep disruption, he recommended adding a low-dose sustained-release form of melatonin, citing a meta-analysis of 14 studies showing reduced sleep latency and a separate review supporting improved sleep quality. He also enrolled the patient in free sleep hygiene coaching with an in-clinic health improvement practitioner. This two-pronged approach—pharmacologic melatonin to ease the transition and non-drug sleep hygiene for long-term maintenance—is now a standard part of his deprescribing toolkit for sedatives in the elderly.

The speaker detailed the numbers: an 11% relative risk reduction for cardiovascular events versus a 43% higher risk of major bleeding. The risks increase with age, and guidelines now explicitly state that for those without established cardiovascular disease (no prior heart attack or stroke), the harms of aspirin exceed the benefits. He acknowledged very specific exceptions—patients with very high Lp(a) or extensive coronary artery calcium—but emphasized that none applied to his active 80-year-old patient who had been on aspirin for years. The speaker used the guideline shift to stop aspirin in two of his three case studies, noting that this is one of the most common unnecessary medications he sees when new patients transfer into his practice.

The speaker presented patient 3, a mid-70s diabetic with heart failure and an HbA1c of 6.7%, which he considered too aggressive given the patient's age and frailty. He explained that clinical guidelines now recommend a target of 8% for frail older individuals with multiple health problems. The danger of tight control is severe hypoglycemia, which can lead to falls—one of the biggest threats to independence. He therefore cut the Lantus insulin dose by half, stopped gliclazide (a sulfonylurea), and simultaneously added empagliflozin 10 mg, an SGLT2 inhibitor that does not cause hypoglycemia and is strongly indicated for heart failure. This approach simultaneously reduced the fall risk from low blood sugar while providing cardiorenal protection.

The speaker detailed each phase. Phase 1 involves collecting a complete medication list, noting any adverse effects, and understanding the patient's health status and personal goals. Phase 2 applies shared decision-making: the physician educates the patient on each drug's benefits and harms in their current context, and the patient weighs this against their own priorities and risk tolerance to decide if stopping is appropriate. Phase 3 is the implementation—deciding which medications to taper or stop, how to do it (e.g., gradual dose reduction), and scheduling follow-up to monitor for adverse reactions or return of symptoms. He stressed that the body doesn't always react as expected, so flexibility and adjustment are essential. He also flagged high-risk populations: those with multiple health problems, multiple care transitions, limited life expectancy, difficulty adhering to regimens, older age, frailty, or dementia. This framework now underpins his approach to every polypharmacy patient.